PATENT CLAIM ANALYSIS

Application Number: 16279733
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["424", "144100"]

Abstract:
Provided are a pharmaceutical composition for preventing or treating cancer and a method of preventing or treating cancer using the same. Cancer may be effectively prevented or treated using the pharmaceutical composition and method.

Claim (Index 3):
The method of  claim 1 , wherein the anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibody inhibits signal transduction or reduces expression of CTLA4.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 99.0
- Lexical Diversity: 1.56522
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15549513', '15921512', '14755989', '14310848', '16188120']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7136513723507942
- 35 USC 102 Novelty (BERT): 0.5241102297822027
- Combined Prediction Score: 0.6946972580939351
- Mean Citation Score: 236.176128
- Max Citation Score: 343.4528
- Similarity Product: 334.5969210285187

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test